NEWTON,
Mass., Nov. 25, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company's senior management team will participate at the Piper
Sandler 36th Annual Healthcare Conference in a fireside
chat on Tuesday, December 3 at 11:30 a.m. ET in
New York, NY.
A live webcast of the fireside chat can be accessed under
"Events & Presentations" in the Investor section of the
Company's
website, https://investors.karyopharm.com/events-presentations,
and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a fundamental
mechanism of oncogenesis. Karyopharm's lead compound and
first-in-class, oral exportin 1 (XPO1) inhibitor,
XPOVIO® (selinexor), is approved in the U.S. and
marketed by the Company in three oncology indications. It has also
received regulatory approvals in various indications in a growing
number of ex-U.S. territories and countries,
including Europe and the United Kingdom (as
NEXPOVIO®) and China. Karyopharm has a focused
pipeline targeting indications in multiple high unmet need cancers,
including in multiple myeloma, endometrial cancer, myelofibrosis,
and diffuse large B-cell lymphoma (DLBCL). For more information
about our people, science and pipeline, please visit
www.karyopharm.com, and follow us on LinkedIn and on X at
@Karyopharm.
XPOVIO® and NEXPOVIO® are
registered trademarks of Karyopharm Therapeutics Inc. Any other
trademarks referred to in this release are the property of their
respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-piper-sandler-36th-annual-healthcare-conference-302314838.html
SOURCE Karyopharm Therapeutics Inc.